US Broker Ratings

Nutex Health Inc. (NUTX) Stock Analysis: Capitalizing on a Potential 117.83% Upside in Healthcare

Nutex Health Inc. (NASDAQ: NUTX) has emerged as a compelling player in the healthcare sector, particularly within the medical care facilities industry. With a market capitalization..

Rocket Pharmaceuticals, Inc. (RCKT)

⚠️ No article content returned.

..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a 64% Upside Potential in the Healthcare Sector

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stands out in the healthcare sector with its focus on pain management solutions, a vital niche within the drug manufacturing industry...

Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with a Promising 28% Potential Upside

Investors looking to tap into the burgeoning healthcare sector might want to take a closer look at Neuropace, Inc. (NASDAQ: NPCE), a trailblazer in the medical..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a 35% Upside Potential Amid Biotech Innovations

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company, is attracting significant investor attention due to its promising pipeline aimed at treating severe autoimmune diseases. With..

Arbutus Biopharma (ABUS) Stock Analysis: Unveiling an 11.5% Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS) stands as a significant player in the biotechnology sector, capturing investor attention with its focus on developing novel therapeutics for infectious..

AbCellera Biologics Inc. (ABCL)

⚠️ No article content returned.

..

Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Exploring a Potential 94% Upside in the Biotech Arena

Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology company, is gaining attention in the healthcare sector with its ambitious pursuit of adeno-associated virus-based gene therapies. Headquartered..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a 38.82% Upside Potential in the Biotech Sector

ArriVent BioPharma, Inc. (AVBP), a clinical-stage biopharmaceutical company, is making waves in the biotechnology industry with its promising pipeline of cancer therapies. With a market capitalization..

Spyre Therapeutics, Inc. (SYRE) Investor Outlook: Exploring a 22% Potential Upside in the Biotech Sector

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a promising player in the biotechnology sector, stands out with a compelling potential upside of 22.53%, catching the attention of investors..

Simulations Plus, Inc. (SLP) Stock Analysis: Exploring a 67.61% Potential Upside in Healthcare Software Solutions

Simulations Plus, Inc. (NASDAQ: SLP) stands prominently in the healthcare sector, specializing in health information services. This U.S.-based company has carved a niche in the drug..

Replimune Group, Inc. (REPL) Stock Analysis: Evaluating a 59.82% Potential Upside in Oncolytic Immunotherapy

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, is pioneering the development of oncolytic immunotherapies designed to activate the immune system against cancer. While its..

Immunome, Inc. (IMNM) Stock Analysis: Exploring a 52.79% Potential Upside with Strong Buy Consensus

Immunome, Inc. (NASDAQ: IMNM), a burgeoning player in the biotechnology sector, is capturing the attention of investors with its promising therapeutic innovations and a robust consensus..

InMode Ltd. (INMD) Stock Analysis: Unveiling an 18.63% Potential Upside in the Medical Devices Sector

InMode Ltd. (NASDAQ: INMD), a prominent player in the healthcare sector, specifically within the medical devices industry, is headquartered in Yokne’am, Israel. Known for its innovative..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring the 136% Potential Upside for Biotech Investors

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is capturing attention in the healthcare sector, particularly among biotechnology investors, due to its promising portfolio and substantial potential upside. With..

Cronos Group Inc. (CRON) Stock Analysis: Navigating a 47% Revenue Surge Amid Market Challenges

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the cannabinoid industry, is capturing investor attention despite a challenging market landscape. With a notable 47% revenue..

Geron Corporation (GERN) Stock Analysis: Exploring a 101% Potential Upside in Biotech

Geron Corporation (NASDAQ: GERN), a notable player in the biotechnology sector, offers an intriguing investment proposition with a potential upside of 101.18% according to analyst targets...

Phibro Animal Health Corporation (PAHC) Stock Analysis: An Investor’s Perspective on Growth Potential and Market Position

Phibro Animal Health Corporation (NASDAQ: PAHC), a significant player in the healthcare sector, specifically in the drug manufacturing of specialty and generic products, is attracting investor..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 187.53% Upside in the Biotechnology Sector

In the ever-evolving biotechnology sector, Niagen Bioscience, Inc. (NASDAQ: NAGE) stands out with its innovative approach to healthy aging and a remarkable potential upside of 187.53%..

uniQure N.V. (QURE) Stock Analysis: Navigating a 129.74% Potential Upside in Biotechnology

Investors with a keen eye on the biotechnology sector might find uniQure N.V. (NASDAQ: QURE) an intriguing prospect, particularly considering its potential upside of 129.74%. As..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds